IM Cannabis Corp.
IM Cannabis Corp is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $1.6M market cap.
Most recent earnings call: Q1 FY25 on May 15, 2025.
14 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks IMCC's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 4/10 quarters with 20% positive reaction rate
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IMCC.
$ curl https://api.spokenalpha.com/v1/companies/IMCCFAQ
Spoken Alpha indexes IMCC's earnings call transcripts at https://spokenalpha.com/companies/IMCC. Each call links to attributed speakers and parsed analyst Q&A. IM Cannabis Corp.'s own investor relations page is at https://investors.imcannabis.com/.
IM Cannabis Corp. (IMCC) held its most recent earnings call on 2025-05-15, covering fiscal Q1 2025.
IM Cannabis Corp. (IMCC) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $3.04 | $2.89 | +5.1% | +0.2% | -1.2% |
| Q4 FY2025 | $2.64 | $2.81 | -5.9% | -0.5% | +1.3% |
| Q3 FY2025 | $3.13 | $3.07 | +1.9% | -1.8% | -3.1% |
| Q2 FY2025 | $3.03 | $3.07 | -1.4% | -2.3% | -4.5% |
| Q1 FY2024 | $2.65 | $2.85 | -6.9% | -3.4% | -2.9% |
| Q4 FY2024 |
| $3.20 |
| $3.08 |
| +3.8% |
| -8.1% |
| -7.1% |
| Q3 FY2024 | $3.17 | $3.02 | +4.9% | -4.0% | -1.1% |
| Q2 FY2024 | $2.99 | $3.16 | -5.3% | -1.3% | -1.1% |
| Q1 FY2023 | $2.68 | $2.94 | -8.7% | -7.2% | -6.2% |
| Q4 FY2023 | $2.95 | $3.13 | -5.6% | +2.0% | -0.2% |